← FDA DRUG APPROVALS

FDA ANDA · ANDA219494

SPIRONOLACTONE

Sponsor: GRAVITI PHARMS

APPLICATION
ANDA219494
TYPE
ANDA
ORIGINAL APPROVAL
2025-01-23
LATEST ACTION
2026-05-12
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SPIRONOLACTONEPrescription
SPIRONOLACTONE 100MG · TABLET · ORAL
SPIRONOLACTONEPrescription
SPIRONOLACTONE 25MG · TABLET · ORAL
SPIRONOLACTONEPrescription
SPIRONOLACTONE 50MG · TABLET · ORAL

Approval history

2026-05-12Labeling · Supplement 2 · standardAP
2025-01-23UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →